Biogen/$BIIB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Biogen
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Ticker
$BIIB
Sector
Primary listing
Employees
7,605
Headquarters
Website
Biogen Metrics
BasicAdvanced
$22B
14.27
$10.45
0.13
-
Price and volume
Market cap
$22B
Beta
0.13
52-week high
$183.19
52-week low
$110.04
Average daily volume
1.6M
Financial strength
Current ratio
2.503
Quick ratio
1.521
Long term debt to equity
37.397
Total debt to equity
37.397
Interest coverage (TTM)
9.82%
Profitability
EBITDA (TTM)
3,222.4
Gross margin (TTM)
76.30%
Net profit margin (TTM)
15.31%
Operating margin (TTM)
24.79%
Effective tax rate (TTM)
14.86%
Revenue per employee (TTM)
$1,310,000
Management effectiveness
Return on assets (TTM)
5.62%
Return on equity (TTM)
9.13%
Valuation
Price to earnings (TTM)
14.265
Price to revenue (TTM)
2.179
Price to book
1.24
Price to tangible book (TTM)
13.06
Price to free cash flow (TTM)
11.887
Free cash flow yield (TTM)
8.41%
Free cash flow per share (TTM)
12.546
Growth
Revenue change (TTM)
3.36%
Earnings per share change (TTM)
31.67%
3-year revenue growth (CAGR)
-2.04%
10-year revenue growth (CAGR)
-0.30%
3-year earnings per share growth (CAGR)
-9.19%
10-year earnings per share growth (CAGR)
-3.39%
What the Analysts think about Biogen
Analyst ratings (Buy, Hold, Sell) for Biogen stock.
Bulls say / Bears say
Biogen beat Q1 2025 revenue estimates with 6% year-over-year growth to $2.43 billion, driven by strong demand for rare disease therapies Skyclarys and Spinraza (Reuters).
The European Commission authorized Leqembi for treating early-stage Alzheimer’s, making it the first EU-approved drug targeting amyloid beta and expanding Biogen’s market access in Europe (Reuters).
FDA approval of Leqembi IQLIK, an at-home injectable maintenance therapy, is expected to enhance patient accessibility and adoption by simplifying treatment relative to IV infusions (Reuters).
Declining sales of core multiple sclerosis medicines during Q1 2025 highlight intensifying competition and revenue pressure in Biogen’s legacy franchise (Reuters).
Biogen lowered its 2025 earnings guidance to $14.50–$15.50 per share, incorporating a $165 million charge from a licensing deal, signaling headwinds from pipeline investments (Reuters).
A U.S. judge ruled Biogen must pay Genentech over $88 million in royalties for Tysabri, introducing unexpected legal liabilities and financial risk (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Biogen Financial Performance
Revenues and expenses
Biogen Earnings Performance
Company profitability
Biogen News
AllArticlesVideos
Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion
Reuters5 days ago
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
Business Wire3 weeks ago
BIIB Stock: Is Biogen Still A Buy After The 14% Spike?
Forbes4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Biogen stock?
Biogen (BIIB) has a market cap of $22B as of October 29, 2025.
What is the P/E ratio for Biogen stock?
The price to earnings (P/E) ratio for Biogen (BIIB) stock is 14.27 as of October 29, 2025.
Does Biogen stock pay dividends?
No, Biogen (BIIB) stock does not pay dividends to its shareholders as of October 29, 2025.
When is the next Biogen dividend payment date?
Biogen (BIIB) stock does not pay dividends to its shareholders.
What is the beta indicator for Biogen?
Biogen (BIIB) has a beta rating of 0.13. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.